Impact: FDA User Fees, Drug Competition and Pricing - Webinar CD/Transcript
Impact: FDA User Fees, Drug Competition and Pricing — An Inside View
User fees affect drug competition at every level. And user fees are a hot topic during the current budget cycle.
Even as you read this, top-level meetings are under way at the FDA, the White House and in Congress. Policy is being hammered out amid great uncertainty under a new FDA administrator, Scott Gottlieb and a new White House that boasts no special background in drug policy or regulation.
If you plan to remain competitive, it’s time to get up to speed.
Washington insiders Alex Brill and Nancy Bradish Myers Esq. share insights, make forecasts, and help you deal with a fast-changing regulatory and policy landscape. You’ll gain an understanding of:
- How the FDA affects drug competition at every level — brand-to-brand, brand-to-generic, generic-to-generic, biologic-to-biosimilar
- Expedited approvals and economic incentives — how the FDA promotes drug competition
- Five ways Congress and the FDA can boost competition and the likelihood of each
- What to expect from the Gottlieb FDA
- And much more!
The Washington landscape is changing fast. Stay competitive! Discover what you need to know now.